NeOnc Technologies CEO Heshmatpour Buys 37,000 Shares at Discount to Financing Price

NeOnc Technologies Holdings (NTHI) CEO Amir F. Heshmatpour bought 37,000 shares at $3.6654 apiece, totaling $136,000, after the company announced a $15 million registered direct offering at $4.20 per share. This purchase is notable as Heshmatpour has been buying NTHI repeatedly and the company plans to request a Type B meeting with the FDA to discuss the potential registrational path for NEO100. The recent clinical data for NEO100 in recurrent IDH1-mutant high-grade glioma showed a 48.9% six-month progression-free survival rate and a 26.09-month median overall survival.